Heterogeneity of chronic obstructive pulmonary disease exacerbations: A two-axes classification proposal

The Lancet Respiratory Medicine

Volumn 3, Issue 9, 2015, Pages 729-734

  Lopez Campos, Jose Luis ^a,b   Agustí, Alvar ^b,c  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; C REACTIVE PROTEIN; COPEPTIN; CORTICOSTEROID; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 1BETA; PROCALCITONIN; BIOLOGICAL MARKER;

BACTERIAL INFECTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDICATION; ENVIRONMENTAL FACTOR; HOSPITALIZATION; HUMAN; NOTE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); VIRAL RESPIRATORY TRACT INFECTION; CLASSIFICATION; CLINICAL DECISION MAKING; DISEASE COURSE; PATHOLOGY; PROCEDURES; SEVERITY OF ILLNESS INDEX;

BIOMARKERS; CLINICAL DECISION-MAKING; DISEASE PROGRESSION; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX;

EID: 84941174542     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(15)00242-8     Document Type: Note

References (78)

1. Wedzicha JA, Seemungal TA COPD exacerbations: defining their cause and prevention. Lancet 2007, 370:786-796.
2. Piquet J, Chavaillon JM, David P, et al. High-risk patients following hospitalisation for an acute exacerbation of COPD. Eur Respir J 2013, 42:946-955.
3. Anzueto A, Leimer I, Kesten S. Impact of frequency of COPD exacerbations on pulmonary function, health status and clinical outcomes. Int J Chron Obstruct Pulmon Dis; 4: 245-51.
4. Geitona M, Hatzikou M, Steiropoulos P, et al. The cost of COPD exacerbations: a university hospital-based study in Greece. Respir Med 2011, 105:402-409.
5. Soler-Cataluna JJ, Martinez-Garcia MA, Roman Sanchez P, et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005, 60:925-931.
6. Vestbo J, Hurd SS, Agusti AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013, 187:347-365.
7. Hurst JR Exacerbation phenotyping in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2011, 184:625-626.
8. Agusti A, Calverley PM, Decramer M, Stockley RA, Wedzicha JA Prevention of exacerbations in chronic obstructive pulmonary disease: knowns and unknowns. Chronic Obstr Pulm Dis 2014, 1:166-184.
9. Beghe B, Verduri A, Roca M, et al. Exacerbation of respiratory symptoms in COPD patients may not be exacerbations of COPD. Eur Respir J 2013, 41:993-995.
10. Lopez-Campos JL, Calero C, Lopez-Ramirez C Exacerbations or complications? Redefining the concepts in COPD. Int J Clin Pract 2014, 68:1048.
11. Kersul AL, Iglesias A, Rios A, et al. Molecular mechanisms of inflammation during exacerbations of chronic obstructive pulmonary disease. Arch Bronconeumol 2011, 47:176-183.
12. Wedzicha JA, Brill SE, Allinson JP, et al. Mechanisms and impact of the frequent exacerbator phenotype in chronic obstructive pulmonary disease. BMC Med 2013, 11:181.
13. Seemungal T, Harper-Owen R, Bhowmik A, et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001, 164:1618-1623.
14. Rangelov K, Sethi S Role of infections. Clin Chest Med 2014, 35:87-100.
15. Molyneaux PL, Mallia P, Cox MJ, et al. Outgrowth of the bacterial airway microbiome after rhinovirus exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013, 188:1224-1231.
16. Huang YJ, Sethi S, Murphy T, et al. Airway microbiome dynamics in exacerbations of chronic obstructive pulmonary disease. J Clin Microbiol 2014, 52:2813-2823.
17. Sethi S, Evans N, Grant BJ, et al. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002, 347:465-471.
18. Agusti A, MacNee W, Donaldson K, et al. Hypothesis: does COPD have an autoimmune component?. Thorax 2003, 58:832-834.
19. Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med 2011, 184:662-671.
20. Gao P, Zhang J, He X, Hao Y, Wang K, Gibson PG Sputum inflammatory cell-based classification of patients with acute exacerbation of chronic obstructive pulmonary disease. PloS One 2013, 8:e57678.
21. Stolz D, Christ-Crain M, Bingisser R, et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest 2007, 131:9-19.
22. Bafadhel M, McKenna S, Terry S, et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Am J Respir Crit Care Med 2012, 186:48-55.
23. Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987, 106:196-204.
24. Soler N, Esperatti M, Ewig S, et al. Sputum purulence-guided antibiotic use in hospitalised patients with exacerbations of COPD. Eur Respir J 2012, 40:1344-1353.
25. Miravitlles M, Kruesmann F, Haverstock D, et al. Sputum colour and bacteria in chronic bronchitis exacerbations: a pooled analysis. Eur Respir J 2012, 39:1354-1360.
26. Clark TW, Medina MJ, Batham S, et al. C-reactive protein level and microbial aetiology in patients hospitalised with acute exacerbation of COPD. Eur Respir J 2015, 45:76-86.
27. Peng C, Tian C, Zhang Y, et al. C-reactive protein levels predict bacterial exacerbation in patients with chronic obstructive pulmonary disease. Am J Med Sci 2013, 345:190-194.
28. Gilbert DN Procalcitonin as a biomarker in respiratory tract infection. Clin Infect Dis 2011, 52(suppl 4):S346-S350.
29. Christ-Crain M, Jaccard-Stolz D, Bingisser R, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 2004, 363:600-607.
30. Schuetz P, Christ-Crain M, Thomann R, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA 2009, 302:1059-1066.
31. Christ-Crain M, Stolz D, Bingisser R, et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2006, 174:84-93.
32. Schuetz P, Muller B, Christ-Crain M, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev 2012, 9. CD007498.
33. Daniels JM, Schoorl M, Snijders D, et al. Procalcitonin vs C-reactive protein as predictive markers of response to antibiotic therapy in acute exacerbations of COPD. Chest 2010, 138:1108-1115.
34. Falsey AR, Becker KL, Swinburne AJ, et al. Utility of serum procalcitonin values in patients with acute exacerbations of chronic obstructive pulmonary disease: a cautionary note. Int J Chron Obstruct Pulmon Dis 2012, 7:127-135.
35. Chang CH, Tsao KC, Hu HC, et al. Procalcitonin and C-reactive protein cannot differentiate bacterial or viral infection in COPD exacerbation requiring emergency department visits. Int J Chron Obstruct Pulmon Dis 2015, 10:767-774.
36. Tanriverdi H, Ornek T, Erboy F, et al. Comparison of diagnostic values of procalcitonin, C-reactive protein and blood neutrophil/lymphocyte ratio levels in predicting bacterial infection in hospitalized patients with acute exacerbations of COPD. Wien Klin Wochenschr 2015, published online Jan 14. 10.1007/s00508-014-0690-6.
37. Stolz D, Christ-Crain M, Morgenthaler NG, et al. Plasma pro-adrenomedullin but not plasma pro-endothelin predicts survival in exacerbations of COPD. Chest 2008, 134:263-272.
38. Stolz D, Christ-Crain M, Morgenthaler NG, et al. Copeptin, C-reactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPD. Chest 2007, 131:1058-1067.
39. Matsumoto H Serum periostin: a novel biomarker for asthma management. Allergol Int 2014, 63:153-160.
40. Jia G, Erickson RW, Choy DF, et al. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. J Allergy Clin Immunol 2012, 130:647. 54.e10.
41. Parulekar AD, Atik MA, Hanania NA Periostin, a novel biomarker of TH2-driven asthma. Curr Opin Pulm Med 2014, 20:60-65.
42. Bhowmik A, Seemungal TA, Donaldson GC, et al. Effects of exacerbations and seasonality on exhaled nitric oxide in COPD. Eur Respir J 2005, 26:1009-1015.
43. Papi A, Bellettato CM, Braccioni F, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med 2006, 173:1114-1121.
44. Agusti AG, Villaverde JM, Togores B, et al. Serial measurements of exhaled nitric oxide during exacerbations of chronic obstructive pulmonary disease. Eur Respir J 1999, 14:523-528.
45. Antus B, Barta I, Horvath I, et al. Relationship between exhaled nitric oxide and treatment response in COPD patients with exacerbations. Respirology 2010, 15:472-477.
46. Aaron SD, Donaldson GC, Whitmore GA, et al. Time course and pattern of COPD exacerbation onset. Thorax 2012, 67:238-243.
47. Quintana JM, Esteban C, Barrio I, et al. The IRYSS-COPD appropriateness study: objectives, methodology, and description of the prospective cohort. BMC Health Serv Res 2011, 11:322.
48. Arostegui I, Esteban C, Garcia-Gutierrez S, et al. Subtypes of patients experiencing exacerbations of COPD and associations with outcomes. PloS One 2014, 9:e98580.
49. Jones PW, Chen WH, Wilcox TK, et al. Characterizing and quantifying the symptomatic features of COPD exacerbations. Chest 2011, 139:1388-1394.
50. Steer J, Gibson J, Bourke SC The DECAF Score: predicting hospital mortality in exacerbations of chronic obstructive pulmonary disease. Thorax 2012, 67:970-976.
51. Tabak YP, Sun X, Johannes RS, et al. Development and validation of a mortality risk-adjustment model for patients hospitalized for exacerbations of chronic obstructive pulmonary disease. Med Care 2013, 51:597-605.
52. Diamantea F, Kostikas K, Bartziokas K, et al. Prediction of hospitalization stay in COPD exacerbations: the AECOPD-F score. Respir Care 2014, 59:1679-1686.
53. Shorr AF, Sun X, Johannes RS, et al. Validation of a novel risk score for severity of illness in acute exacerbations of COPD. Chest 2011, 140:1177-1183.
54. Quintana JM, Esteban C, Unzurrunzaga A, et al. Predictive score for mortality in patients with COPD exacerbations attending hospital emergency departments. BMC Med 2014, 12:66.
55. Roche N, Chavaillon JM, Maurer C, et al. A clinical in-hospital prognostic score for acute exacerbations of COPD. Respir Res 2014, 15:99.
56. Torres A, Sibila O, Ferrer M, et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA 2015, 313:677-686.
57. Brightling CE Biomarkers that predict and guide therapy for exacerbations of chronic obstructive pulmonary disease. Ann Am Thorac Soc 2013, 10(suppl):S214-S219.
58. Gunen H, Hacievliyagil SS, Yetkin O, et al. The role of nebulised budesonide in the treatment of exacerbations of COPD. Eur Respir J 2007, 29:660-667.
59. Yilmazel Ucar E, Araz O, Meral M, et al. Two different dosages of nebulized steroid versus parenteral steroid in the management of COPD exacerbations: a randomized control trial. Med Sci Monit 2014, 20:513-520.
60. Larsen MV, Janner JH, Nielsen SD, Friis-Møller A, Ringbaek T, Lange P Bacteriology in acute exacerbation of chronic obstructive pulmonary disease in patients admitted to hospital. Scand J Infect Dis 2009, 41:26-32.
61. Meijvis SC, Hardeman H, Remmelts HH, et al. Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial. Lancet 2011, 377:2023-2030.
62. Sellares J, Lopez-Giraldo A, Lucena C, et al. Influence of previous use of inhaled corticoids on the development of pleural effusion in community-acquired pneumonia. Am J Respir Crit Care Med 2013, 187:1241-1248.
63. Ferrer M, Torres A, Martinez R, et al. Inhaled corticosteroids and systemic inflammatory response in community-acquired pneumonia: a prospective clinical study. Respirology 2014, 19:929-935.
64. Brusse-Keizer M, VanderValk P, Hendrix R, et al. Necessity of amoxicillin clavulanic acid in addition to prednisolone in mild-to-moderate COPD exacerbations. BMJ Open Respir Res 2014, 1:e000052.
65. Wilson R, Anzueto A, Miravitlles M, et al. Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results. Eur Respir J 2012, 40:17-27.
66. Daniels JM, Snijders D, de Graaff CS, et al. Antibiotics in addition to systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010, 181:150-157.
67. Woods JA, Wheeler JS, Finch CK, et al. Corticosteroids in the treatment of acute exacerbations of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2014, 9:421-430.
68. Vollenweider DJ, Jarrett H, Steurer-Stey CA, et al. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012, 12. CD010257.
69. Husebo GR, Bakke PS, Aanerud M, et al. Predictors of exacerbations in chronic obstructive pulmonary disease-results from the Bergen COPD cohort study. PloS One 2014, 9:e109721.
70. Pozo-Rodríguez F, Castro-Acosta A, Alvarez CJ, et al. Determinants of between-hospital variations in outcomes for patients admitted with COPD exacerbations: findings from a nationwide clinical audit (AUDIPOC) in Spain. Int J Clin Pract 2015, published online Feb 4. 10.1111/ijcp.12601.
71. Quintana JM, Esteban C, Garcia-Gutierrez S, et al. Predictors of hospital admission two months after emergency department evaluation of COPD exacerbation. Respiration 2014, 88:298-306.
72. Steer J, Gibson GJ, Bourke SC Predicting outcomes following hospitalization for acute exacerbations of COPD. QJM 2010, 103:817-829.
73. Roberts CM, Stone RA, Lowe D, et al. Co-morbidities and 90-day outcomes in hospitalized COPD exacerbations. COPD 2011, 8:354-361.
74. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010, 363:1128-1138.
75. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997, 336:243-250.
76. Aujesky D, Obrosky DS, Stone RA, et al. Derivation and validation of a prognostic model for pulmonary embolism. Am J Respir Crit Care Med 2005, 172:1041-1046.
77. Tofan F, Rahimi-Rad MH, Rasmi Y, et al. High sensitive C-reactive protein for prediction of adverse outcome in acute exacerbation of chronic obstructive pulmonary disease. Pneumologia 2012, 61:160-162.
78. Collins FS, Varmus H A new initiative on precision medicine. N Engl J Med 2015, 372:793-795.